S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:PODD

Insulet (PODD) Stock Forecast, Price & News

$283.09
+1.75 (+0.62%)
(As of 04:33 PM ET)
Compare
Today's Range
$280.49
$284.05
50-Day Range
$272.48
$330.23
52-Week Range
$192.33
$335.91
Volume
392,800 shs
Average Volume
718,039 shs
Market Capitalization
$19.73 billion
P/E Ratio
238.29
Dividend Yield
N/A
Price Target
$330.00

Insulet MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
16.6% Upside
$330.00 Price Target
Short Interest
Healthy
4.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
-0.02mentions of Insulet in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$12.92 M Sold Last Quarter
Proj. Earnings Growth
49.64%
From $1.37 to $2.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

319th out of 986 stocks

Surgical & Medical Instruments Industry

36th out of 98 stocks


PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet Corporation: Margins Are On A Diet
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Expert Ratings for Insulet
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BTIG Sticks to Its Buy Rating for Insulet (PODD)
StockNews.com Begins Coverage on Insulet (NASDAQ:PODD)
Insulet Co. (NASDAQ:PODD) Short Interest Update
Insulet (NASDAQ:PODD) PT Raised to $329.00 at Barclays
See More Headlines

PODD Price History

PODD Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,600
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$330.00
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$260.00
Forecasted Upside/Downside
+17.3%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$4.60 million
Pretax Margin
0.37%

Debt

Sales & Book Value

Annual Sales
$1.31 billion
Cash Flow
$2.24 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
69,069,000
Market Cap
$19.61 billion
Optionable
Optionable
Beta
0.80

Social Links


Key Executives

  • James R. Hollingshead
    President, Chief Executive Officer & Director
  • Prem Singh
    Senior Vice President-Global Operations
  • Wayde Dwight McMillan
    Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly
    Senior Vice President & Medical Director
  • Mark Field
    Group Vice President-Software Engineering













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PODD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

13 Wall Street analysts have issued 12 month target prices for Insulet's shares. Their PODD share price forecasts range from $260.00 to $370.00. On average, they predict the company's stock price to reach $330.00 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 on January 1st, 2023. Since then, PODD shares have decreased by 4.0% and is now trading at $282.51.
View the best growth stocks for 2023 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its earnings results on Thursday, May, 4th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.14. The medical instruments supplier earned $358.10 million during the quarter, compared to analyst estimates of $330.21 million. Insulet had a trailing twelve-month return on equity of 17.29% and a net margin of 0.04%. Insulet's revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its second quarter 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.24 million-$389.22 million, compared to the consensus revenue estimate of $362.68 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (3.24%), Clearbridge Investments LLC (2.24%), Geode Capital Management LLC (2.13%), Bank of New York Mellon Corp (0.83%), Gateway Advisory LLC (0.79%) and William Blair Investment Management LLC (0.69%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, Eric Benjamin, John A Fallon, Luciana Borio, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $282.51.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $19.69 billion and generates $1.31 billion in revenue each year.

How many employees does Insulet have?

The company employs 2,600 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -